Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myelofibrosis: early-phase trial registry
29 of 62 indexed Myelofibrosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #228 of 28,707 conditions by registered trial count.
62 US clinical trials · 29 currently recruiting · #228 of 28,707 conditions by registered trial count
Myelofibrosis: 62 US clinical trials tracked, 29 recruiting.
Myelofibrosis is the subject of 62 registered US clinical trials on ClinicalTrials.gov, 29 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 47 in Phase 1-2 (earlier-stage). The most active sponsor is Incyte Corporation, running 4 of these trials.
Enrollment posture brief
Registry condition myelofibrosis
OPEN 29 | RECR 47% | LATE 7 | EARLY 47 | RANK #228 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Breast Cancer Female (47% recruiting · 47 trials)
Myelofibrosis lists 29 open slots (47% of 62 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myelofibrosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myelofibrosis is recruiting above its size-band peers.
29 of 62 indexed trials (46.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Myelofibrosis trials is spread across many organizations.
Incyte Corporation accounts for 4 of 62 trials (6.5%). 49 distinct sponsors appear on at least one study for this condition label.
-
Most Myelofibrosis trials plan to enrol fewer than 100 people.
Median target enrolment is 44 among the 62 trials that report a genuine target (sentinel values excluded). 39 of those (62.9%) plan for fewer than 100 participants.
-
Myelofibrosis research is mostly interventional.
58 interventional and 4 observational studies make up this index (93.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
62 total, page 1 of 2
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
MPN Research Foundation
NCT07362225
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Center for International Blood and Marrow Transplant Research
NCT02934477
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Kartos Therapeutics
NCT06479135
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Merck Sharp & Dohme
NCT06351631
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
NCT03314974
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Sumitomo Pharma America
NCT04176198
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT06059391
A Telehealth Advance Care Planning Intervention
University of Rochester
NCT05875805
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT01962636
Quantitative MRI for Myelofibrosis
University of Michigan Rogel Cancer Center
NCT01973881
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Disc Medicine
NCT05320198
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
Telios Pharma
NCT04655118
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical
NCT04771572
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Epigenetix
NCT05488548
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Telios Pharma
NCT05280509
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Karyopharm Therapeutics
NCT05980806
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
Karen Ballen, MD
NCT05233618
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
Memorial Sloan Kettering Cancer Center
NCT06773195
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
Geron Corporation
NCT05371964
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
M.D. Anderson Cancer Center
NCT06345495
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
University of Southern California
NCT06063486
Momelotinib During and After HCT in Myelofibrosis
Massachusetts General Hospital
NCT07104799
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
University of California, Irvine
NCT05123365
A Safety and Tolerability Study of Jaktinib
Suzhou Zelgen Biopharmaceuticals Co.
NCT05279001
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Cellenkos
NCT05423691
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
Omar Aljitawi
NCT03964506
Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis
University of Utah
NCT05535764
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Marina Kremyanskaya
NCT05025488
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
University of California, Irvine
NCT07281781
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Novartis Pharmaceuticals
NCT04603495
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Karyopharm Therapeutics
NCT04562389
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Geron Corporation
NCT04576156
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Celgene
NCT04717414
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Bristol-Myers Squibb
NCT04817007
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Incyte Corporation
NCT04279847
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
Karyopharm Therapeutics
NCT04562870
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
NCT02530034
A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
Memorial Sloan Kettering Cancer Center
NCT03069326
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
Ohio State University Comprehensive Cancer Center
NCT05972577
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
NCT03289910
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Dana-Farber Cancer Institute
NCT03912064
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center
NCT03480360
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
Galecto Biotech AB
NCT04679870
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
Incyte Corporation
NCT04640025
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Jacqueline Garcia, MD
NCT05455294
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT04060277
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Incyte Corporation
NCT00509899
Genetic Analysis of Gray Platelet Syndrome
National Human Genome Research Institute (NHGRI)
NCT00069680
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
Eli Lilly and Company
NCT01520220
Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
Stemline Therapeutics
NCT02268253
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 30 |
| Phase 2 | 17 |
| Phase 3 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Myelofibrosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myelofibrosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myelofibrosis page
62 registered trials, 29 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 29 Myelofibrosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Incyte Corporation sponsors the most Myelofibrosis trials on record, review their full trial history before evaluating a specific study. See Incyte Corporation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myelofibrosis condition card totals 62 registered trials; most-linked intervention Ruxolitinib; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.